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Objectives. To compare the estimation of coronary
heart disease (CHD) risk by the Framingham risk
score (FRS) and the Copenhagen risk score (CRS)
using Dutch population data.
Design. Comparison of CHD risk estimates from FRS
and CRS. CHD risk-estimations for each separate risk
factor.
Setting. Urk, the Netherlands.
Subjects. A total of 408 ﬁshermen from Urk, aged
30–65 years, without pre-existing cardiovascular
disease.
Main outcome measures. Absolute CHD risk
estimates.
Results. The average 10-year risk for CHD was
signiﬁcantly different between the FRS (4.6%, SD
5.0) and the CRS (3.2%, SD 4.1). The correlation
betweenthetwoestimateswas0.94(P < 0.001).The
Bland–Altman ﬁgure shows a large proportion of
agreement, but with an increasing difference with
increasingaveragerisk.Whenexaminingtheseparate
risk factors age, total cholesterol, HDL cholesterol
andsystolicbloodpressureandsmoking,thereappear
differences between the two risk functions.
Conclusion. Using Dutch population data,
differences were found for the calculation of CHD
risk with the FRS and the CRS. Further research
must be carried out to examine the validity of these
risk functions in the Dutch population.
Keywords: coronary heart disease, Netherlands,
prevention, risk assessment, risk factors.
Introduction
Various studies have shown that the risk for
coronary heart disease (CHD) is determined by a
number of risk factors and their interactions. The
most important factors are age, gender, smoking,
blood pressure, cholesterol level and diabetes mell-
itus [1–3]. The major established risk factors explain
approximately 75% of the occurrence of CHD within
populations [4].
Accurate estimation of the absolute risk is not
always straightforward. Physicians understand the
relative importance of the various risk factors, but
they tend to overestimate the absolute risk when
assessing individual patients [5, 6]. The total risk for
CHD is best estimated by considering the cumulative
effect of various risk factors [7]. For optimal calcu-
lation of the risk for CHD, multivariate techniques
have been used to develop so-called ‘risk scores’. A
risk score is a mathematical formula reﬂecting the
relationship between the risk factors and the inci-
dence of speciﬁc end-points. Risk-scores make it
possible to calculate both the absolute and the
relative risks for different cardiovascular disease
(CVD) outcomes. Risk scores are an important
tool for prevention and also in allowing for a
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occur. The risk calculation from the Framingham
Heart Study is most often used [7].
In practice, calculating the risk for CHD and CVD
is important in identifying high-risk patients, moti-
vating patients for intervention, and generating a
risk proﬁle when assessing the indication for phar-
maceutical treatment in primary prevention of CVD.
Assessment of absolute risk for CHD and CVD has
become an accepted basis for the use of cholesterol-
lowering drugs and the use of antihypertensive
agents [8–20]. Absolute risk assessment is also
needed to calculate the number needed to treat
(NNT) and to evaluate the cost-effectiveness of
treatment, and to assess the populations implica-
tions of treatment policies based on random control
trail evidence [21].
In the clinical guidelines, the indication for
treating hypercholesterolaemia is generally based
on the absolute risk for CHD, whilst for hypertension
the general risk for CVD is used [9, 10, 19, 20, 22].
Although there is widespread acceptance
amongst Dutch family physicians of the national
guidelines, it has been documented that the guide-
lines are used only partly or not at all in actual
practice situations [23]. The implementation of
these guidelines may become more universal when
physicians are offered practical and efﬁcient meth-
ods for informing and motivating their patients,
thereby improving their insight. Translating the
theoretical chance of disease into realistic conceiv-
able realities for the patient is one of the most
important practical problems faced by physicians
[24]. As the simplicity and quality of CVD risk
calculation methods increase, treatment implemen-
tation becomes more efﬁcient. Furthermore it is
supposed that when evaluating the indication for
treatment with antihypertensive medication, efﬁ-
ciency could be increased when an absolute risk
calculation for CVD is used [25].
For rational use, clinicians need to be conﬁdent
that absolute risk predictions can be transported to
other settings beyond where they were originally
developed. To assess the applicability of risk predic-
tions to other populations, it is important to look at
the distribution, incidence and impact of the differ-
ent risk factors and the incidence of deﬁned end-
points. Possible variations, occurring amongst the
different populations, must be examined and taken
into account [26, 27].
Recently, a European risk calculation program,
named PRECARD
, was developed in Denmark [28].
PRECARD
 calculates the absolute and relative risks
for CHD, and also the expected efﬁcacy of any
interventions. The PRECARD
 program uses the
Copenhagen Risk Score (CRS) to calculate the
absolute risk for CHD. PRECARD
 also generates
an individualized patient-focused health advice.
In the present study, the absolute CHD risk
estimate of the CRS is compared with the risk
estimate of the Framingham Risk Score (FRS) as
currently used in various European cardiovascular
guidelines. Using Dutch population data, the results
obtained with the two absolute risk calculations are
compared, and the risk assessments per individual
risk factor are examined.
Material and methods
To be able to study the difference in outcome of the
risk assessment of the CRS and the risk calculation
used in the FRS, both calculations were applied to
data on a population of ﬁshermen from Urk. Urk is a
former island in the Netherlands, with a large
population of North Sea ﬁshermen. Data on major
cardiovascular risk factors were gathered since
1989 during the obliged annual check-up. These
data were and are used to study the prevalence of
cardiovascular risk factors and to study longitudinal
changes. The methods and the study design have
been described elsewhere [29]. For the risk calcula-
tion, data from 406 men aged 30–65 years were
used, from whom all pertinent information was
known. The general characteristics for this popula-
tion are summarized in Table 1.
In the PRECARD
 program, the CRS is used to
calculate the absolute risk for myocardial infarcts
(MI), CHD, cerebrovascular disorders and total
mortality. The CRS is based on the results of
11 765 individuals from two large Danish studies,
the Glostrup Population Study and the Copenhagen
City Heart Study, with a total of 120 000 person-
years. The Cox regression model was used to analyse
the data, with age as time variable. One of the
limitations of the CRS is that the risk for CHD,
cerebrovascular disorders and overall mortality can
be reliably measured only for individuals aged 30–
70 years, who have an annual risk between 0.5 and
4.0%. As is true for all risk scores, the accuracy of
the risk calculation is limited when a patient’s risk
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therefore not recommended for such patients.
The FRS described by Anderson et al. is used as
comparison in the presented study, because it is
used as a risk assessment instrument in many
protocols throughout Europe [7]. This risk score is
based on data from the Framingham Heart Study,
a longitudinal American study, initiated in 1948
and involving 5209 individuals. Data regarding
their cardiovascular risk factors and any develop-
ment of CVD have been, and are currently still
being collected. Using these data, risk scores
were developed, with which the risks for CHD,
cerebrovascular disorders and CVD can be calcu-
lated. The FRS is based on data collected during
12 years of follow-up on the original Framingham
cohort and on the Framingham offspring cohort
[7]. Recently new sex-speciﬁc models for primary
and secondary CHD have been produced [30, 31].
The FRS is often preferred, as its calculations are
based on an extensive data collection, and because
it offers the possibility of calculating the risk for
CHD, cerebrovascular and CVD for both men and
women aged 30–74 years. The FRS is available for
practical usage in card, tabular and computer
format.
Simpliﬁed forms of the FRS by Anderson et al.
have been incorporated in European, New Zealand,
UK and Dutch national guidelines for the manage-
ment of hypercholesterolaemia and hypertension
[9–18]. This risk score is based on a parametric
regression model to provide predicted probabilities
for CHD.
In Table 2, an overview is given of the risk factors,
which are used for the CRS and the FRS. In our
study, no information was available about left
ventricularhypertrophy onelectrocardiogram(ECG).
In the calculation for all individuals, this variable
was therefore considered negative.
The deﬁnitions for CHD used for the CRS and the
FRS are different [7]. The CRS uses a deﬁnition for
‘hard’ CHD, which includes fatal and nonfatal MI.
The FRS provides estimates of total CHD and
includes angina pectoris and coronary insufﬁciency
in addition to the two aforementioned conditions.
Generally, estimates for ‘hard’ CHD are about two-
thirds to three-fourths of those of total CHD [20]. To
make the two risk estimates comparable with regard
to end-point deﬁnition, the approximate equivalen-
cy for ‘hard’ CHD per age-category have been
calculated for the FRS (modiﬁed from Wilson et al.)
[31].
For each individual, the estimated CHD risk
was calculated by each risk function, using the
variables required and expressed as a percentage per
10 years. The comparison involves studying the
convergent validity of the CRS to the FRS. This
means that it was determined whether or not the
results obtained with the CRS calculation are
consistent with the results obtained using the FRS.
The Student’s t-test for paired evaluations was
used to compare the results obtained with the two
risk calculations. The regression coefﬁcients of the
risk estimates with the associated 95% conﬁdence
intervals were calculated. The estimates for both
calculations are presented graphically. The ‘line of
identity’ and the regression line are indicated in the
Table 1 General characteristics of the study population
Mean (SD)
or n (%)
Number 406
Age (years) 41.2 (8.0)
Smokers (number of men) 217 (53.4%)
Ex-smokers (number of men) 114 (28.1%)
Positive family history (number of men) 102 (25.1%)
Prior coronary heart disease (number of men) 0
Diabetes mellitus type 2 (number of men) 7 (1.7%)
Body mass index (kg m
)2) 28.4 (3.7)
Systolic blood pressure (mmHg) 140 (19)
Total cholesterol (mmol L
)1) 6.3 (1.2)
HDL cholesterol (mmol L
)1) 1.17 (0.31)
Table 2 Variables of the Copenhagen and Framingham Risk
Scores
Copenhagen Risk Score Framingham Risk Score
Non-modiﬁable risk factors
Age Age
Gender Gender
Diabetes mellitus Diabetes mellitus
Genetic predisposition –
Previous coronary heart disease –
– Left ventricular
hypertrophy on ECG
Modiﬁable risk factors
Smoking Smoking
Total cholesterol –
HDL cholesterol –
– Total/HDL cholesterol
Body mass index –
Systolic blood pressure Systolic blood pressure
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which would occur when identical results were
obtained with the two methods. The correlation
between the two risk calculations was analysed
using the method described by Bland and Altman
[32].
To discover differences in the risk estimates per
separate risk factors, ﬁgures were generated, which
show the risk estimate resulting from the two
methods for the continuous variables such as age,
total cholesterol, HDL cholesterol and systolic blood
pressure. In these ﬁgures, the moving average is
calculated so that ﬂuctuations, caused by a small
number of observations, are ﬁltered out. For the
categorical variable ‘smoking’, a box-plot shows the
risk estimation for the two risk functions for both
smokers and nonsmokers.
Results
The average risk for CHD, as calculated with the
CRS, is 3.2% (SD 4.1) for 10 years, with a lower
limit of 0.1% and an upper limit of 32.4%. The
median value is 1.8% for 10 years. The average risk
as calculated with FRS is 4.6% (SD 5.0) for 10 years,
with a lower limit of 0.1% and an upper limit of
28.4%. The median is 2.9% for 10 years. The
average difference between the two risk estimates
is 1.4% (SD 1.8) for 10 years, with a lower limit of
)4.1% and an upper limit of 8.3% and a median of
0.9% for 10 years. There is a signiﬁcant (P < 0.001)
difference between the two risk estimates, although
the correlation between the two is high (r ¼ 0.94,
P < 0.001).
The risk estimates, derived from the two methods,
are presented in Fig. 1(a). The deviation of the
regression line from the line of identity is signiﬁcant
for the intercept ()0.23, 95% conﬁdence interval –
0.26 to )0.20) and for the slope ()0.35, 95%
conﬁdence interval – 0.54 to )0.16) (Fig. 1a). The
risk calculated with the FRS is globally 1.3 more
than the risk calculated with the CRS.
The Bland–Altman ﬁgure shows the amount of
agreement between the two measures (Fig. 1b). A
large portion of the calculated differences falls
between two standard deviations from the average
difference. There is, however, a systematic difference
between the two measures, which becomes larger
with a higher risk estimate. This is represented as
an increase in the difference associated with an
increase of the average risk. The variability (range)
of the difference increases as the average risk
increases.
It can be concluded, that the two measures do not
completely agree throughout the spectrum of the
risk estimation. The correlation between the differ-
ence and the average risk estimate is 0.51, which
indicates that the difference increases, when the
average risk estimate increases [33].
In Fig 2a–e, risk estimates are presented for each
risk factor individually. The ﬁgures show how it
becomes apparent, that the differences between the
CRS and the FRS are determined by all studied
variables. Higher risk estimates for the FRS com-
pared with the CRS are seen, when the variables
Framingham risk score for CHD 
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cholesterol and smoking are considered.
Discussion
This comparison between the CRS, which is the risk
assessment used in the PRECARD
 program, and
the FRS shows, that there are clear differences
between these two methods for calculating absolute
CHD risk in a Dutch population. Although there is a
high correlation between the two risk calculations,
the CRS results in a lower absolute risk estimate
than the FRS. The difference between the two risk
calculations becomes larger with a higher risk
estimate. A difference between the two calculations
was seen when the variables age, systolic blood
pressure, total cholesterol, HDL cholesterol and
smoking were examined.
The FRS by Anderson et al. used in this compar-
ison has been adopted in various European coun-
tries, in accord with guidelines of European
cardiovascular societies. The FRS provides estimates
of total CHD, whilst the CRS gives risk estimates for
only ‘hard’ CHD end-points (MI and CHD death) [7].
To compare the risk estimates of the FRS with the
CRS, the risk estimations of the former were adjusted
to approximate equivalents for ‘hard’ CHD. The
adjustment of end-points may have inﬂuenced
the results. It is however questionable whether the
problem with end-points deﬁnitions can explain the
difference in risk estimation between the two used
risk scores. Haq et al. compared risk estimations
from the Framingham, prospective cardiovascular
Mu ¨nster (PROCAM), Dundee and British regional
heart study (BRHS) in a high-risk group of hyper-
tensive men [21]. Although a difference in total and
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Fig. 2 Risk estimates for coronary heart disease with the Framingham and Copenhagen risk scores for each individual risk factor. (a) age;
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respectively, the Framingham and the other popu-
lations, close agreement was found between the
Framingham, PROCAM and Dundee risk functions.
This indicates that in our study, explanations other
than the differences in end-points might also
account for the found results.
Recently, a new Framingham risk scoring specif-
ically applied to ‘hard’ CHD is described in the
National Cholesterol Education Program Adult
Treatment Panel III Report (NCEP ATP III) [20].
This risk scoring derives from an update of the
Framingham database and methodology reported by
Wilson et al. [20, 30]. Ten-year absolute CHD risk is
assessed with a point scoring system using categor-
ical variables. Comparison of this new risk score
with the CRS shows large differences in the risk
estimates for ‘hard’ CHD (Fig. 3). The risk estimates
of the new risk score are also clearly out of line with
the FRS by Anderson et al. if adjusted for ‘hard’ CHD
end-points (Fig. 4). The reason for the overestima-
tion in this new FRS is unknown at present. Exact
prediction equations should therefore be provided as
soon as possible (as they have not been published
yet), so that details can be inspected.
Another supposed explanation for the differences
is the difference in risk factors used. The CRS
considers total cholesterol and HDL cholesterol
separately, and includes the variables ex-smoker,
family history for CVD, and body mass index (BMI).
In the FRS, the ratio of total cholesterol/HDL
cholesterol and left ventricular hypertrophy, identi-
ﬁed on ECG, are used.
Differences between the populations on which the
risk functions are based, might be a third explan-
ation for the difference in the risk estimates. The CRS
is based on data gathered since 1977, in Denmark,
Europe, whereas the FRS is based on older data
gathered since 1968 in the United States of America.
There has been a dramatic decline in mortality from
CHD over the past decades (also in the United States),
apparently as a result of a decline in the incidence of
individual risk factors and from prevention efforts.
Therefore, different predictive coefﬁcients may result
from the two studies, as a consequence of changing
trends in population risk-factor levels and CHD-
event rates. The difference in the incidence of
CHD between the two populations may also inﬂu-
ence the absolute risk estimate. Sans et al. showed
that in the period 1990–92, the age-adjusted
mortality for CHD in men in the Netherlands
was 315 per 100 000 per year compared with
423 per 100 000 per year in Denmark [34].
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100 000 person-years in the Framingham popula-
tion compared with 385 in the Danish Glostrup
population [35].
Various studies have shown that the important
risk factors for CHD are the same for most
populations [36]. However, using the relationship
between cardiovascular risk factors and CHD is too
heterogeneous to be applied equally to populations
differing in ethnic origin [26]. Support for this
claim could be found in our study, when the
differences between the absolute risk calculations
with respect to the factors such as age, systolic
blood pressure, total cholesterol, HDL cholesterol,
and smoking were considered. However, traditional
experience in comparing population groups belong-
ing to different cultures shows that the relative risk
bound to different levels in risk factors is similar
across cultures, whilst the absolute risk can be
very different [37]. A recent study examining the
generalizability of risk functions from diverse
populations, found that the prediction of absolute
risk was not very accurate in most of the cases,
when a model derived from one study was applied
to a different study [38]. This was also found in a
study by Menotti et al. [39]. They based risk
functions on data obtained from North European
and South European countries, and made a
comparison. The relation of risk factors to events
had a similar trend across the different popula-
tions. However, when the North European model
was used to examine the South European popula-
tion, the absolute risk estimation was too high
(ratio of about 1.5), and when the South European
model was applied to the North European popula-
tion, the absolute risk estimation was too low
(ratio of about 0.5). Using a correction factor for
the differing incidences would improve the accu-
racy of the estimation when the same model is
used in different cultures.
Finally, the difference between the outcomes of
the comparison of the two risk scores, in total and
for the separate risk factors, may be explained by the
difference in analysis methods upon which the
calculations are based. The CRS is based on Cox’s
regression model, whilst the FRS is based on a
parametric statistical model.
In a study by Thomsen et al., a cross validation of
risk scores for CHD based on data from the Glostrup
Population Studies and the Framingham Heart
Study was made [35]. They found that the risk
scores correctly ordered the risk of the individuals in
the other population. Although there are clear
differences in the general risk proﬁles between the
Glostrup and the Framingham populations, the
relative risks are not signiﬁcantly different. However,
the risk score based on the Framingham data
signiﬁcantly overestimated the absolute CHD risk
in the Glostrup population and vice versa. Schroll
and Larsen compared the coefﬁcients of one cohort
of the Glostrup Population Study to the Framingham
Heart Study and found the Framingham coefﬁcients
to be generally higher [40]. The differences in risk
estimates found in our study, were not only caused
by differences in end-point deﬁnitions, used risk
factors and analysing methods, but can also be
explained by differences in the incidence of CHD and
differences in the relationship between risk factors
and absolute CHD risk.
The European treatment guidelines for hypercho-
lesterolaemia and hypertension are based on abso-
lute risk calculations, which use the Framingham
risk function [8–19]. The result of the comparison of
the American and the European data sets discussed
above reveals a marked difference between these two
absolute risk calculations. Using the CRS instead of
the FRS for diagnostic and treatment indications
would result in large differences. This raises the
question: which risk calculation can be most reliably
used for the Dutch population?
Already different research results which examine
the validity of the FRS for different populations have
been reported. Most studies report an overestimation
of the absolute risk, but a relative risk estimation of
reasonable accuracy shows that the relative import-
ance of these risk factors is similar in several
populations. In the Seven Countries Study, Keys
et al. report that the FRS overestimates the risk for
CHD [41]. Orford et al. found the Framingham
prediction model to underestimate absolute risk of
CHD in low-risk and overestimate in high-risk
subjects of the Normative Ageing Study [42]. A
study of D’Agostino et al. showed that the FRS
overestimated risk in some ethnic groups, and
recalibration for risk-factor prevalence and CHD
incidence rates corrected this [43]. Several studies
have shown that the FRS tended to overpredict
absolute risk in populations with a low observed
CHD mortality, and underpredict in populations
with a high CHD mortality [38, 44]. However, a
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English hypertensive men, calculation of the aver-
age risk for CHD with the FRS is largely in
agreement with calculations using the German
PROCAM and the English DUNDEE risk score [21].
Recent research conducted by Ramachrandran et al.
has demonstrated that the absolute risk estimate for
CHD as calculated with the FRS for English individ-
uals is reliable when the yearly risk is more than
1.5%. When this risk is less than 1.5%, the FRS
underestimates the absolute risk [45]. It was con-
cluded that the accuracy of the risk estimate
according to the FRS and its modiﬁed derivatives,
seems to be acceptable for some North European
populations. Nevertheless, as of yet, no results are
available for reporting the validity of the application
of the FRS to assess the Dutch population.
Likewise, little is known concerning the reliability
of risk estimates using the CRS for other populations.
It may be reasonable to assume that the lifestyle
characteristics of the Dutch population have more in
common with the Danish population than with the
American population, upon which the FRS is based.
This also accounts for the CHD mortality. This
difference mentioned above indicates that, concern-
ing the CHD mortality, the Dutch population is more
comparable with the Glostrup population than with
the Framingham population.
The presented study used data from a population
of men with high risk factor levels [29]. All men
have the same profession and nationality, which
may limit generalizability to some extent. However,
the results are relevant to general practice, as
because of their high risk factor levels, this group
of men is likely to be comparable with those who are
screened in primary care for prevention of CHD.
Therefore this group of men is an appropriate
selection to be used to evaluate risk estimations,
rather than selected groups with higher risks based
on hypertension, lipid disorders, diabetes or subse-
quent CHD.
In this study, no data on cardiovascular risk
factors in women were available.
Our study did not intend to assess whether the
FRS and CRS are accurate in the tested population.
To study this, Dutch population data on CHD events
rates over time are needed, which are currently not
available. However, both the FRS and the CRS are
developed to be used in Northern European popula-
tions and should therefore be suitable to be used in
the Dutch population [45]. As differences in risk
estimations were found, the question does present
itself whether a risk calculation based on Danish
population or Northern American data would be
more accurate for the Dutch population. The results
of the present comparison invite further research by
examining the external validity of risk calcula-
tions for the Dutch population and testing them
against a risk function based on Dutch population
data. The accuracy of absolute risk prediction,
particularly at the extremes of multivariate risk,
may be questionable and validation of these risk
functions is important in the light of the profound
impact of these estimates on the management of
individual patients and the allocation of community
resources.
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